Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload
| Autor: | Bing Han, Zhangbiao Long, Yali Du, Bo Hou, Miao Chen, Feng Feng |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Risk medicine.medical_specialty Iron Overload Adolescent Iron Chelating Agents Gastroenterology Ventricular Function Left Iron chelation Hemoglobins Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Blood Transfusion Prospective Studies Aplastic anemia Decreased serum ferritin Pancreas Aged Aged 80 and over Ejection fraction medicine.diagnostic_test business.industry Myelodysplastic syndromes Anemia Aplastic Magnetic resonance imaging Hematology General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging Liver Myelodysplastic Syndromes 030220 oncology & carcinogenesis Ferritins Female Observational study Hemoglobin business Follow-Up Studies 030215 immunology |
| Zdroj: | Acta Haematologica. 138:119-128 |
| ISSN: | 1421-9662 0001-5792 |
| Popis: | Background: This study focuses on the iron overload (IOL) of patients with transfused aplastic anemia (AA) or a low/intermediate-1 risk of myelodysplastic syndrome (MDS). Methods: Ninety-two AA or MDS patients with IOL were prospectively recruited. Clinical data were collected every 6 months, and organ magnetic resonance imaging T2* values were collected annually. Patients with IOL were chelated. Results: Serum ferritin was correlated with liver T2* and pancreatic T2* in the AA and MDS groups. Transfusion amounts were correlated with serum ferritin values, liver T2*, and pancreatic T2* in the AA group. At the 6-month and 1-year evaluations, patients with sufficient chelation experienced significant decreases in serum ferritin, and those with decreased serum ferritin experienced an obvious increase in hemoglobin. At their 1-year-follow-up, patients with adequate chelation showed significant increases in hepatic T2*, cardiac T2*, and left ventricular ejection fraction (LVEF). Patients with decreased serum ferritin (including those without chelation) experienced an increase in hemoglobin, hepatic T2*, cardiac T2*, and LVEF. Conclusion: The transfusion amount was more reliable at predicting IOL in patients with AA than in those with MDS. Adequate iron chelation can decrease serum ferritin levels and may improve hepatic T2*, cardiac T2*, and LVEF levels. A decrease in serum ferritin, even in the absence of chelation, may also benefit patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|